Opus Genetics
IRD
16 hedge funds and large institutions have $930K invested in Opus Genetics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 14 closing their positions.
1.12% more ownership
Funds ownership: 0% → 1.12% (+1.1%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
43% less funds holding
Funds holding: 28 → 16 (-12)
48% less capital invested
Capital invested by funds: $1.78M → $930K (-$845K)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$196K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.22K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$701 |
| 4 |
Morgan Stanley
New York
|
+$678 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$497 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$454K |
| 2 |
BlackRock
New York
|
-$59.6K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$53K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$51K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$35K |
IRD Hedge Fund Activity: Q2 2019 in Review
16 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2019, worth a combined $930K — down 48% from $1.78M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IRD and 2 opened new positions — a net loss of 12 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $196K. The largest seller was Vanguard Group, cutting an estimated $454K.
- 16 institutional investors held Opus Genetics (IRD) as of Q2 2019, down from 28 in Q1 2019.
- Funds reported $930K of Opus Genetics stock for Q2 2019, down 48% quarter-over-quarter.
- 2 funds opened new Opus Genetics positions in Q2 2019 and 14 closed out, a net change of -12 holders.
- The largest Opus Genetics buyer in Q2 2019 was Renaissance Technologies, an estimated $196K added.
- The largest Opus Genetics seller in Q2 2019 was Vanguard Group, an estimated $454K sold.
Based on aggregated 13F filings for Q2 2019.